Adj. EPS $7.48, est. $5.59 Rev. $24.40B, est. $22.52B Mounjaro rev. $10.7B, est. $9.95B Zepbound rev. $5.35B, est. $5.01B Foundayo rev. $184M, est. $231.2M Acquired IPR&D charges $4.57/share Sees FY rev. $91B to $92B, saw $85B to $87B Sees FY Adj. EPS $35 to $36, saw $35.50 to $36.50
Eli Lilly’s experimental drug eloralintide, combined with Zepbound, delivered 23.3% average weight loss over roughly 11 months, compared with 14.8% for Zepbound alone in patients with Type 2 diabetes. However, 11–27% discontinued the combination due to side effects, highlighting tolerability concerns. Lilly plans to advance the treatment into late-stage…
*ELI LILLY - TO SUBMIT BIOLOGICS LICENSE APPLICATION FOR RETATRUTIDE IN Q1 2027 $LLY